Internal Medicine IV, University Hospital of Schleswig Holstein, Campus Kiel, Kiel, Germany.
Internal Medicine III, University Hospital of Schleswig Holstein, Campus Kiel, Rosalind-Franklin-Str.12, 24105, Kiel, Germany.
Clin Res Cardiol. 2018 Feb;107(2):148-157. doi: 10.1007/s00392-017-1166-2. Epub 2017 Sep 22.
To assess, whether cardiac catheterization via radial access prevents contrast-induced nephropathy.
Contrast-induced nephropathy (CIN) is a major clinical problem which accounts for more than 10% of acute kidney injury cases in hospitalized patients. Protective measures such as the infusion of isotonic saline solution or acetylcysteine have not consistently been proven to prevent acute kidney injury (AKI). However, there is growing evidence that radial access for coronary angiography and coronary intervention is associated with a lower incidence of AKI compared to femoral access.
In a retrospective monocentric analysis, 2937 patients that had undergone cardiac catheterization were examined. Up to 2013, coronary intervention was performed primarily via the femoral artery in our hospital; thereafter, interventions were primarily done via the radial artery. In the cohort under study, 1141 patients had received catheterization using the radial access while 1796 were examined via the femoral artery. No significant differences were found in the two groups regarding the amount of iodinated contrast medium applied [femoral group: 180 (120-260) ml; radial group: 180 (120-250) ml; P = 0.438]. A total of 400 (13.6%) patients developed acute kidney injury (AKI) after cardiac catheterization (85.3% AKI stage 1; 12.8% AKI stage 2; 2% AKI stage 3). AKI was significantly less frequent in patients that had received radial access compared to patients with femoral access (10.1 vs. 15.9%, P < 0.001). Multivariate regression analysis showed that patient age (1.03/year; 95% CI 1.02-1.04/year; P < 0.001), the amount of contrast media applied (OR 1.003/ml; 95% CI 1.002-1.004/ml; P < 0.001), acute coronary syndrome (OR 2.01, 95% CI 1.52-2.66; P < 0.001), CKD (OR 1.62, 95% CI 1.50-1.70; P < 0.001), pre-existing heart failure (OR 1.27, 95% CI 1.00-1.42 P = 0.007), previous myocardial infarction (OR 1.34, 95% CI 1.15-1.49; P = 0.001), diabetes (OR 1.25, 95% CI 1.04-1.41; P = 0.020) and serum creatinine before the procedure (1.45/mg/dl; 95% CI 1.24-1.69/mg/dl; P < 0.001) were important risk factors for the occurrence of AKI. Our analysis points to a significant risk reduction using radial access (OR 0.65; 95% CI 0.51-0.83; P < 0.001). Interestingly, this reduction in risk was also evident in patients with CKD (OR 0.59; 95% CI 0.41-0.87; P = 0.007). The superiority of radial access was particularly obvious in the subgroup of patients with acute coronary syndrome (13.1% AKI in the radial access group vs. 23.6% AKI in the femoral access group, OR 0.52; 95% CI 0.34-0.81; P = 0.003).
Our study shows that cardiac catheterization using radial access bears significantly lower risk of AKI than cardiac catheterization via femoral access. The advantage of radial access in acute coronary syndrome regarding morbidity and mortality could partly be explained by the here demonstrated reduced risk for AKI. Thus, radial access should be preferred in patients at risk for AKI.
评估经桡动脉入路行心脏导管检查是否能预防造影剂肾病。
造影剂肾病(CIN)是一个主要的临床问题,占住院患者急性肾损伤病例的 10%以上。虽然有保护措施,如输注等渗盐水或乙酰半胱氨酸,但尚未一致证明这些措施能预防急性肾损伤(AKI)。然而,越来越多的证据表明,与股动脉入路相比,经冠状动脉造影和冠状动脉介入治疗的桡动脉入路与较低的 AKI 发生率相关。
在一项回顾性单中心分析中,检查了 2937 例接受心脏导管检查的患者。直到 2013 年,我们医院的冠状动脉介入治疗主要通过股动脉进行;此后,干预主要通过桡动脉进行。在研究队列中,1141 例患者接受了桡动脉入路的导管检查,1796 例患者通过股动脉进行了检查。两组间应用的碘造影剂量无显著差异[股动脉组:180(120-260)ml;桡动脉组:180(120-250)ml;P=0.438]。心脏导管检查后共有 400(13.6%)例患者发生急性肾损伤(AKI)(85.3% AKI 第 1 期;12.8% AKI 第 2 期;2% AKI 第 3 期)。与股动脉入路患者相比,桡动脉入路患者 AKI 发生率显著降低(10.1%比 15.9%,P<0.001)。多变量回归分析显示,患者年龄(每增加 1 岁:1.03/年;95%CI 1.02-1.04/年;P<0.001)、应用造影剂量(OR 1.003/ml;95%CI 1.002-1.004/ml;P<0.001)、急性冠状动脉综合征(OR 2.01,95%CI 1.52-2.66;P<0.001)、慢性肾脏病(OR 1.62,95%CI 1.50-1.70;P<0.001)、预先存在的心力衰竭(OR 1.27,95%CI 1.00-1.42,P=0.007)、既往心肌梗死(OR 1.34,95%CI 1.15-1.49;P=0.001)、糖尿病(OR 1.25,95%CI 1.04-1.41;P=0.020)和手术前的血清肌酐(1.45/mg/dl;95%CI 1.24-1.69/mg/dl;P<0.001)是 AKI 发生的重要危险因素。我们的分析表明,使用桡动脉入路显著降低了风险(OR 0.65;95%CI 0.51-0.83;P<0.001)。有趣的是,在慢性肾脏病患者中,这种风险的降低也很明显(OR 0.59;95%CI 0.41-0.87;P=0.007)。桡动脉入路的优越性在急性冠状动脉综合征患者亚组中尤为明显(桡动脉组 AKI 发生率为 13.1%,股动脉组 AKI 发生率为 23.6%,OR 0.52;95%CI 0.34-0.81;P=0.003)。
本研究表明,与股动脉入路相比,经桡动脉入路行心脏导管检查发生 AKI 的风险显著降低。桡动脉入路在急性冠状动脉综合征患者中的优势在发病率和死亡率方面可能部分归因于这里证明的 AKI 风险降低。因此,在有 AKI 风险的患者中,应优先选择桡动脉入路。